APCO WORLDWIDE LLC (ON BEHALF OF HIKMA PHARMACEUTICALS USA INC.)

Lobbying client · District of Columbia · filed 2026 to 2026

Public relations and strategic communications

$40,000 Reported spend

3 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 3 filings. Everything on this page is grouped by the client's LDA id (72618), not by name.

Firms hired 1

BURRELL INTERNATIONAL GROUP LLC $40,000 3 filings

Reported by year 1 year

2026 $40,000 3 filings

Issues lobbied 1

Health Issues 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 1
SENATE 1

Recent filings 3 total

Q2

BURRELL INTERNATIONAL GROUP LLC

2nd Quarter (Apr 1 - June 30) 2026 · $30,000 income · posted Jul 19, 2026

View → Q1

BURRELL INTERNATIONAL GROUP LLC

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $10,000 income · posted Apr 20, 2026

View → RR

BURRELL INTERNATIONAL GROUP LLC

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 17, 2026

View →

Foreign entities disclosed 1

HIKMA PHARMACEUTICALS PLC United Kingdom named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Affiliated organisations 1

HIKMA PHARMACEUTICALS USA INC. United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.